UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000039726
Receipt No. R000045308
Scientific Title Survey using web questionnaire on problems of antihypertensive medication therapy and patient preference for renal denervation in hypertensive patients
Date of disclosure of the study information 2020/03/10
Last modified on 2020/09/07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Survey using web questionnaire on problems of antihypertensive medication therapy and patient preference for renal denervation in hypertensive patients
Acronym Survey using web questionnaire on problems of antihypertensive medication therapy and patient preference for renal denervation in hypertensive patients
Scientific Title Survey using web questionnaire on problems of antihypertensive medication therapy and patient preference for renal denervation in hypertensive patients
Scientific Title:Acronym Survey using web questionnaire on problems of antihypertensive medication therapy and patient preference for renal denervation in hypertensive patients
Region
Japan

Condition
Condition hypertension
Classification by specialty
Medicine in general Cardiology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To clarify the problem of antihypertensive medication therapy and patient preference for renal denervation
Basic objectives2 Others
Basic objectives -Others 1.Problems of antihypertensive medication therapy
2.Patient preference for renal denervation
Trial characteristics_1 Others
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes 1.Problems of antihypertensive medication therapy
2.Patient preference for renal denervation
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1.Subjects who consent to participate in this study
2.Age >=20years and <=80years at the time of obtaining consent
3.Subjects who go to a hospital regularly for hypertension therapy at least once in three months
4.Subjects who take one or more antihypertensive agents.
5.Subjects who measure their blood pressure regularly.
Key exclusion criteria Medical staff(including doctor, pharmacist, nurse)
Subjects engaged in pharmaceutical, medical devices companies, media, market research, and advertising/ marketing industries.
Target sample size 4000

Research contact person
Name of lead principal investigator
1st name Keisuke
Middle name
Last name Ozawa
Organization Terumo Corporation
Division name Clinical Development Department
Zip code 163-1450
Address Tokyo Opera City Tower 49F, 3-20-2,Nishi-shinjuku,Shinjuku-ku, Tokyo 163-1450, Japan
TEL 03-6742-8500
Email Keisuke_ozawa@terumo.co.jp

Public contact
Name of contact person
1st name Keisuke
Middle name
Last name Ozawa
Organization Terumo Corporation
Division name Clinical Development Department
Zip code 163-1450
Address Tokyo Opera City Tower 49F, 3-20-2,Nishi-shinjuku,Shinjuku-ku, Tokyo 163-1450, Japan
TEL 03-6742-8500
Homepage URL
Email Keisuke_ozawa@terumo.co.jp

Sponsor
Institute Terumo Corporation
Institute
Department

Funding Source
Organization Terumo Corporation
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Terumo ethics Review Board
Address 1500, inokuchi,nakaimachi,ashigarakami-gun kanagawa, Japan
Tel 0465-81-4115
Email Hirokazu_Hasegawa@terumo.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 03 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2020 Year 03 Month 03 Day
Date of IRB
2020 Year 03 Month 03 Day
Anticipated trial start date
2020 Year 03 Month 12 Day
Last follow-up date
2020 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Survey using web questionnaire on problems of antihypertensive medication therapy and patient preference for renal denervation in hypertensive patients

Management information
Registered date
2020 Year 03 Month 06 Day
Last modified on
2020 Year 09 Month 07 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045308

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.